Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Transcription factors of the nuclear factor κB (NF-κB) family are central coordinating regulators of the host defence responses to stress, injury and infection. Aberrant NF-κB activation also contributes to the pathogenesis of some of the most common current threats to global human health, including chronic inflammatory diseases, autoimmune disorders, diabetes, vascular diseases and the majority of cancers. Accordingly, the NF-κB pathway is widely considered an attractive therapeutic target in a broad range of malignant and non-malignant diseases. Yet, despite the aggressive efforts by the pharmaceutical industry to develop a specific NF-κB inhibitor, none has been clinically approved, due to the dose-limiting toxicities associated with the global suppression of NF-κB. In this review, we summarise the main strategies historically adopted to therapeutically target the NF-κB pathway with an emphasis on oncology, and some of the emerging strategies and newer agents being developed to pharmacologically inhibit this pathway.
Original languageEnglish
Article number50
Number of pages35
JournalBiomedicines
Volume5
Issue number3
DOIs
Publication statusPublished - 22 Aug 2017
Externally publishedYes

Fingerprint

Drug Industry
Type 1 Diabetes Mellitus
Vascular Diseases
Chronic Disease
Transcription Factors
Wounds and Injuries
Infection
Neoplasms
Therapeutics
Global Health

Cite this

Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity. / Bennett, Jason.

In: Biomedicines, Vol. 5, No. 3, 50, 22.08.2017.

Research output: Contribution to journalArticle

@article{319d5f10e9ad46a0b6fb96f796779f4e,
title = "Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity",
abstract = "Transcription factors of the nuclear factor κB (NF-κB) family are central coordinating regulators of the host defence responses to stress, injury and infection. Aberrant NF-κB activation also contributes to the pathogenesis of some of the most common current threats to global human health, including chronic inflammatory diseases, autoimmune disorders, diabetes, vascular diseases and the majority of cancers. Accordingly, the NF-κB pathway is widely considered an attractive therapeutic target in a broad range of malignant and non-malignant diseases. Yet, despite the aggressive efforts by the pharmaceutical industry to develop a specific NF-κB inhibitor, none has been clinically approved, due to the dose-limiting toxicities associated with the global suppression of NF-κB. In this review, we summarise the main strategies historically adopted to therapeutically target the NF-κB pathway with an emphasis on oncology, and some of the emerging strategies and newer agents being developed to pharmacologically inhibit this pathway.",
author = "Jason Bennett",
year = "2017",
month = "8",
day = "22",
doi = "10.3390/biomedicines5030050",
language = "English",
volume = "5",
journal = "Biomedicines",
issn = "2227-9059",
publisher = "MDPI AG",
number = "3",

}

TY - JOUR

T1 - Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity

AU - Bennett, Jason

PY - 2017/8/22

Y1 - 2017/8/22

N2 - Transcription factors of the nuclear factor κB (NF-κB) family are central coordinating regulators of the host defence responses to stress, injury and infection. Aberrant NF-κB activation also contributes to the pathogenesis of some of the most common current threats to global human health, including chronic inflammatory diseases, autoimmune disorders, diabetes, vascular diseases and the majority of cancers. Accordingly, the NF-κB pathway is widely considered an attractive therapeutic target in a broad range of malignant and non-malignant diseases. Yet, despite the aggressive efforts by the pharmaceutical industry to develop a specific NF-κB inhibitor, none has been clinically approved, due to the dose-limiting toxicities associated with the global suppression of NF-κB. In this review, we summarise the main strategies historically adopted to therapeutically target the NF-κB pathway with an emphasis on oncology, and some of the emerging strategies and newer agents being developed to pharmacologically inhibit this pathway.

AB - Transcription factors of the nuclear factor κB (NF-κB) family are central coordinating regulators of the host defence responses to stress, injury and infection. Aberrant NF-κB activation also contributes to the pathogenesis of some of the most common current threats to global human health, including chronic inflammatory diseases, autoimmune disorders, diabetes, vascular diseases and the majority of cancers. Accordingly, the NF-κB pathway is widely considered an attractive therapeutic target in a broad range of malignant and non-malignant diseases. Yet, despite the aggressive efforts by the pharmaceutical industry to develop a specific NF-κB inhibitor, none has been clinically approved, due to the dose-limiting toxicities associated with the global suppression of NF-κB. In this review, we summarise the main strategies historically adopted to therapeutically target the NF-κB pathway with an emphasis on oncology, and some of the emerging strategies and newer agents being developed to pharmacologically inhibit this pathway.

U2 - 10.3390/biomedicines5030050

DO - 10.3390/biomedicines5030050

M3 - Article

VL - 5

JO - Biomedicines

JF - Biomedicines

SN - 2227-9059

IS - 3

M1 - 50

ER -